IL-NIELSENIQ
21.7.2022 13:02:04 CEST | Business Wire | Press release
NielsenIQ is pleased to announce the 2022 recipients of the seventh annual NielsenIQ BASES Design Impact Awards for the consumer-packaged goods (CPG) industry. The global competition recognizes and celebrates best-in-class package redesigns, and the business impacts they make for their companies. This year’s winners include brands that delivered innovative and creative packaging with design concepts that reflected brand vision while supporting the shopper journey.
Sixty brands submitted package redesigns and the NielsenIQ BASES team used the company’s proprietary Retail Measurement Sales (RMS) data to identify which brands demonstrated an increase in sales after the launch of the updated package designs. In addition to evaluating RMS data, NielsenIQ conducted a behavioral survey of 15,000 shoppers to assess individual entries across the shopper journey. Each product was evaluated to determine if it presented a visually appealing, easily identifiable package that allowed consumers to find the product on shelves and engage them to purchase the item. The results unveiled 10 winners across various CPG categories with excellent designs and a measurable increase in sales.
“Our team is thrilled to support and promote inspired brands who deliver fresh, beautifully designed packages that stimulate brand growth and financial successes,” said Andrea Fraboni, Vice President & Global Leader of BASES Design Solutions at NielsenIQ. “This year’s winners embody how effective redesigned packaging can help transform and elevate the bottom line of a brand. These companies did it right and we’re excited to showcase their outstanding accomplishments.”
The winners of the 2022 NielsenIQ BASES Design Impact Award* are:
- L’usine Sliced Multigrain Bread (Parent Company: Almarai; Country: Saudi Arabia)
- Coors Light Beer (Parent Company: Molson Coors Beverage Company; Design Agency: Soulsight; Country: United States)
- Brooke's Oros Beverages (Parent Company: Tiger Brands; Design Agency: Just Design; Country: South Africa)
- Cadbury Old Gold Chocolate (Parent Company: Mondelez International; Design Agency: Bulletproof; Country: Australia)
- Lucozade Energy Drink (Parent Company: Suntory; Country: United Kingdom)
- Nescafé Artesano Coffee (Parent Company: Nestlé; Country: Colombia)
- SSENSE Herbal Tea (Parent Company: SSENSE; Design Agency: Pigeon; Country: Canada)
- Turin Chocolate (Parent Company: Mars; Country: Mexico)
- Speed Stick & Lady Speed Stick (Parent Company: Colgate-Palmolive; Design Agency: Dragon Rouge BZ; Country: Mexico)
- Lay's Potato Chips (Parent Company: PepsiCo; Design Agency: PEP Global Design Team; Country: South Africa)
Learn more about our package design research solutions, the NielsenIQ BASES Design Impact Award, and learnings from this year’s winners by visiting the BASES Design Impact Award web page.
*All products and company names are trademarks of their respective holders. No affiliation or endorsement is expressed or implied.
About NielsenIQ
NielsenIQ, a global information services company, delivers the gold standard in consumer and retail measurement, through the most connected, complete, and actionable understanding of the evolving global, omnichannel consumer. NielsenIQ is the source of confidence for the industries we serve and the pioneer defining the next century of consumer and retail measurement. Our data, connected insights, and predictive analytics optimize the performance of CPG and retail companies, bringing them closer to the communities they serve and helping to power their growth.
NielsenIQ, an Advent International portfolio company, has operations in 90+ markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom